Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.

Heart rhythm - 1 Nov 2013

Khoury Asaad, Marai Ibrahim, Suleiman Mahmoud, Blich Miry, Lorber Avraham, Gepstein Lior, Boulos Monther

Abstract excerpt

BACKGROUND: Calsequestrin-associated catecholaminergic polymorphic ventricular tachycardia (CPVT2) can cause sudden death in young individuals in response to stress. Beta-blockers are the mainstay medical treatment for patients with CPVT2. However, they do not prevent syncope and sudden death in all patients. Flecainide was reported to reduce exercise-induced ventricular arrhythmias (EIVA) in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Calsequestrin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Death, Sudden, Cardiac

Share to Electrocardiography

Share to Exercise Test

Share to Flecainide

Share to Polymorphic Catecholaminergic Ventricular Tachycardia

Share to Tachycardia, Ventricular

Source

Identifiers

PMID: 23954267
DOI: 10.1016/j.hrthm.2013.08.011

Genes

CASQ2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.PMID 23954267Read ↗

Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.Semantic proximity Read ↗

Catecholaminergic Polymorphic Ventricular Tachycardia.Semantic proximity Read ↗

Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.Semantic proximity Read ↗

Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.Semantic proximity Read ↗

Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.Semantic proximity Read ↗

Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.Semantic proximity Read ↗

Catecholaminergic polymorphic ventricular tachycardia.Semantic proximity Read ↗

Long-term Serial Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia on Beta-Blocker and Flecainide TherapySemantic proximity Read ↗

Catecholaminergic polymorphic ventricular tachycardia.Semantic proximity Read ↗

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations - Long-Term Prognosis After Initiation of Medical Treatment.Semantic proximity Read ↗

The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.Semantic proximity Read ↗

Molecular and Electrophysiological Bases of Catecholaminergic Polymorphic Ventricular TachycardiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.